Walsh Roddy, Tadros Rafik, Bezzina Connie R
Department of Clinical and Experimental Cardiology, Heart Centre, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands.
Department of Medicine, Cardiovascular Genetics Center, Montreal Heart Institute and Faculty of Medicine, Université de Montréal, 5000 Belanger, Montreal, QC H1T 1C8, Canada.
Eur Heart J. 2020 Oct 14;41(39):3849-3855. doi: 10.1093/eurheartj/ehaa269.
Rare cardiac genetic diseases have generally been considered to be broadly Mendelian in nature, with clinical genetic testing for these conditions predicated on the detection of a primary causative rare pathogenic variant that will enable cascade genetic screening in families. However, substantial variability in penetrance and disease severity among carriers of pathogenic variants, as well as the inability to detect rare Mendelian variants in considerable proportions of patients, indicates that more complex aetiologies are likely to underlie these diseases. Recent findings have suggested genetic variants across a range of population frequencies and effect sizes may combine, along with non-genetic factors, to determine whether the threshold for expression of disease is reached and the severity of the phenotype. The availability of increasingly large genetically characterized cohorts of patients with rare cardiac diseases is enabling the discovery of common genetic variation that may underlie both variable penetrance in Mendelian diseases and the genetic aetiology of apparently non-Mendelian rare cardiac conditions. It is likely that the genetic architecture of rare cardiac diseases will vary considerably between different conditions as well as between patients with similar phenotypes, ranging from near-Mendelian disease to models more akin to common, complex disease. Uncovering the broad range of genetic factors that predispose patients to rare cardiac diseases offers the promise of improved risk prediction and more focused clinical management in patients and their families.
罕见心脏遗传病通常被认为本质上大致符合孟德尔遗传规律,针对这些病症的临床基因检测基于检测到一个主要致病罕见致病变异,该变异可使对家族成员进行级联基因筛查成为可能。然而,致病变异携带者之间的外显率和疾病严重程度存在显著差异,并且在相当比例的患者中无法检测到罕见的孟德尔变异,这表明这些疾病可能存在更复杂的病因。最近的研究结果表明,一系列人群频率和效应大小的基因变异可能与非遗传因素共同作用,以确定是否达到疾病表达阈值以及表型的严重程度。越来越多有基因特征的罕见心脏病患者队列的出现,使得发现可能是孟德尔疾病可变外显率以及明显非孟德尔罕见心脏病症的遗传病因基础的常见基因变异成为可能。罕见心脏病的遗传结构在不同病症之间以及具有相似表型的患者之间可能有很大差异,范围从近乎孟德尔疾病到更类似于常见复杂疾病的模式。揭示使患者易患罕见心脏病的广泛遗传因素,有望改善风险预测,并为患者及其家人提供更有针对性的临床管理。